Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Non Operating Income: 2017-2025

Historic Non Operating Income for Protagonist Therapeutics (PTGX) over the last 7 years, with Sep 2025 value amounting to $33,000.

  • Protagonist Therapeutics' Non Operating Income fell 76.60% to $33,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $182,000, marking a year-over-year decrease of 30.80%. This contributed to the annual value of $250,000 for FY2024, which is 224.38% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Non Operating Income stood at $33,000 for Q3 2025, which was down 8.33% from $36,000 recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Non Operating Income peaked at $141,000 during Q3 2024, and registered a low of -$195,000 during Q1 2023.
  • Moreover, its 3-year median value for Non Operating Income was $33,000 (2025), whereas its average is $18,182.
  • In the last 5 years, Protagonist Therapeutics' Non Operating Income skyrocketed by 646.15% in 2022 and then crashed by 1,600.00% in 2023.
  • Protagonist Therapeutics' Non Operating Income (Quarterly) stood at -$13,000 in 2021, then surged by 646.15% to $71,000 in 2022, then plummeted by 38.03% to $44,000 in 2023, then dropped by 29.55% to $31,000 in 2024, then slumped by 76.60% to $33,000 in 2025.
  • Its last three reported values are $33,000 in Q3 2025, $36,000 for Q2 2025, and $82,000 during Q1 2025.